The pH-Responsive Liposomes—The Effect of PEGylation on Release Kinetics and Cellular Uptake in Glioblastoma Cells
Open Access
- 25 May 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (6) , 1125
Abstract
Nanomedicine has been, to a certain degree, a success story in the development of superior anticancer therapies. However, there are tumors that remain a huge challenge for nanoformulations, for instance, brain tumors such as glioblastoma, the most common and aggressive brain tumor. To utilize the fact that such tumors are characterized by an acidic extracellular environment, we selected pH-responsive liposomes as a potential drug delivery system for superior delivery to GBM. Liposomes comprising PEGylated lipid of two chain lengths with encapsulated fluorescent marker calcein were characterized and challenged against non-PEGylated vesicles. The in vitro calcein release from three liposomal formulations (<200 nm), namely non-PEGylated (pH-Lip) and PEGylated, pH-Lip–PEG750, and pH-Lip–PEG2000, was followed at three pH conditions to prove the pH-responsiveness. The intracellular delivery of a liposomally encapsulated marker was determined in GL261 glioblastoma cell lines in vitro using both flow cytometry and confocal microscopy. The inclusion of PEG2000 within liposomal formulation resulted in reduced in vitro pH-responsiveness compared to pH-Lip and pH-Lip750. All three pH-responsive liposomal formulations improved intracellular uptake in GL261 cells compared to non-pH-responsive liposomes, with negligible differences regarding PEG length. The proposed formulations should be further evaluated in glioblastoma models.Keywords
Funding Information
- UiT
- publication fund at UiTThe Arctic University of Norway
This publication has 41 references indexed in Scilit:
- Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapyJournal of Clinical Neuroscience, 2011
- Dysregulated pH: a perfect storm for cancer progressionNature Reviews Cancer, 2011
- Delivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and StrategiesAnnual Review of Chemical and Biomolecular Engineering, 2011
- RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II studyBMC Cancer, 2009
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patientsJournal of Neuro-Oncology, 2008
- Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapyCancer Science, 2006
- Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imagingJournal of Controlled Release, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibodyJournal of Controlled Release, 2004
- Sterically Stabilized pH-sensitive Liposomes, INTRACELLULAR DELIVERY OF AQUEOUS CONTENTS AND PROLONGED CIRCULATION IN VIVOJournal of Biological Chemistry, 1997